MedTrace Logo

Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes

NCT06239506 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2024-02-02

No results posted yet for this study

Summary

As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects. The associations between traditional endocrine-disrupting chemicals (EDCs) and type 2 diabetes have been extensively reported in epidemiological studies. To date, however, human-based evidence on the effects of NBFRs and OPFRs is lacking. The investigators conducted a case-control study of 344 participants aged 25-80 years from Shandong Province, East China, to assess potential associations between serum NBFR and OPFR concentrations and etiology of type 2 diabetes for the first time.

Conditions

  • Type 2 Diabetes
  • Novel Brominated Flame Retardants
  • Organophosphate Flame Retardants
  • Fasting Plasma Glucose

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Xiaoling Guan

    lead OTHER

Principal Investigators

  • Tian Hui, Dr. · Shandong First Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06239506 on ClinicalTrials.gov